Last reviewed 2026-04-20 · How we verify

11-Brovincamine (BROVINCAMINE)

Phase 2 active Small molecule

11-Brovincamine (generic name: BROVINCAMINE) is a brovincamine drug. It is currently in Phase 2 development.

BROVINCAMINE is believed to work by modulating certain biological pathways.

BROVINCAMINE, also known as 11-Brovincamine, is a small molecule drug in the brovincamine class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain biological pathways. BROVINCAMINE is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, key safety considerations and approved indications are currently unavailable.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BROVINCAMINE
Drug class	brovincamine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of BROVINCAMINE like a key that unlocks a specific process in the body. By fitting into a particular spot, it can influence how the body works, but the exact details of how it does this are still unclear. This process can potentially lead to changes in how the body functions, but more research is needed to understand the full effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

11-Brovincamine CI brief — competitive landscape report
11-Brovincamine updates RSS · CI watch RSS

Frequently asked questions about 11-Brovincamine

What is 11-Brovincamine?

11-Brovincamine (BROVINCAMINE) is a brovincamine drug.

How does 11-Brovincamine work?

BROVINCAMINE is believed to work by modulating certain biological pathways.

What is the generic name of 11-Brovincamine?

BROVINCAMINE is the generic (nonproprietary) name of 11-Brovincamine.

What drug class is 11-Brovincamine in?

11-Brovincamine belongs to the brovincamine class. See all brovincamine drugs at /class/brovincamine.

What development phase is 11-Brovincamine in?

11-Brovincamine is in Phase 2.

Drug class: All brovincamine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing